This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
by Indrajit Bandyopadhyay
Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.
Align (ALGN) Gains From New Launches, Strategic Partnerships
by Zacks Equity Research
Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye
by Zacks Equity Research
Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
by Zacks Equity Research
Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.
Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
by Zacks Equity Research
On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.
PetMeds (PETS) to Advance Pet Care With New Collaboration
by Zacks Equity Research
PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.
PacBio's (PACB) New Offering to Boost WGS Data Analysis
by Zacks Equity Research
PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.
3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft
by Zacks Equity Research
Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
Zacks.com featured highlights Rev Group, CVR Energy, Cardinal Health, Commercial Vehicle and Archer Daniels Midland
by Zacks Equity Research
Rev Group, CVR Energy, Cardinal Health, Commercial Vehicle and Archer Daniels Midland have been highlighted in this Screen of The Week article.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
by Zacks Equity Research
Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
5 Stocks That Brokers Favor Despite the Ongoing Uncertainty
by Maharathi Basu
We believe that stocks like Rev Group (REVG), CVR Energy (CVI), Cardinal Health (CAH), Commercial Vehicle Group (CVGI) and Archer Daniels (ADM) should be on an investor's watchlist.
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
by Zacks Equity Research
Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.
Globus Medical (GMED) Gains From NuVasive Buyout, Innovation
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease
by Zacks Equity Research
Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
Alcon (ALC) Gains From Growing Market Demand, New Launches
by Zacks Equity Research
Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch
by Zacks Equity Research
ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.
Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships
by Zacks Equity Research
Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.
Haemonetics (HAE) Announces Agreement to Acquire OpSens
by Zacks Equity Research
Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.